HBV Surface Antigen Tests Required Under Proposed Tissue Reg
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of human cellular and tissue-based products should use surface antigen tests for hepatitis B rather than core antibody HBV assays, FDA states in a Sept. 30 proposed rule.